R & D background
R & D pipeline
Two projects are in clinical trial stage:
UP818, a new chemical entity with new mechanism, is intended to be used for Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) by i.v. and for Idiopathic Pulmonary Fibrosis (IPF) by s.c. Phase I study of i.v. on healthy volunteers in Hua Shan Hospital, Shanghai, China, is completing by the end of 2022. Phase II study on ARDS is planning to start in May, 2023. It is planning to submit CTA to Swedish MPA in June, 2023 and start clinical trial phase I in September, 2023, in Sweden.
Montelukast sodium topical sterile gel for anorectal surgery and radiation proctitis. China mainland has been licensed to Shanghai Pharma, who is the sponsor for clinical trial and further development. Phase I study on healthy volunteers has been completed. Phase II studies on the two indications are planning to start in January and February, 2023.
12 patent applications by PCT
First Submission Date
Two in China and one in US have been authorized
Add:Room 201, 202, 203, BuildingA, Block1, No. 800, Qingdai Road, Pudong New District, Shanghai
Copyright ©2022 EnliTISA (Shanghai) Pharmaceutical Co., Ltd. | SEO 沪ICP备2022023966号-1 Powered by www.300.cn